Unresectable Gastrointestinal stromal tumor

DrugDrug NameDrug Description
DB15233AvapritinibA selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors.
DB00619ImatinibA tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
DB08896RegorafenibA kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma.
DrugDrug NameTargetType
DB15233AvapritinibPlatelet derived growth factor receptor alphatarget
DB15233AvapritinibMast/stem cell growth factor receptor Kittarget
DB15233AvapritinibP-glycoprotein 1transporter
DB15233AvapritinibATP-binding cassette sub-family G member 2transporter
DB15233AvapritinibCytochrome P450 3A4enzyme
DB15233AvapritinibCytochrome P450 2C9enzyme
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBreakpoint cluster region proteintarget
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibP-glycoprotein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB00619ImatinibBile salt export pumptransporter
DB00619ImatinibCytochrome P450 2C8enzyme
DB08896RegorafenibCytochrome P450 3A4enzyme
DB08896RegorafenibUDP-glucuronosyltransferase 1-9enzyme
DB08896RegorafenibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08896RegorafenibVascular endothelial growth factor receptor 1target
DB08896RegorafenibVascular endothelial growth factor receptor 2target
DB08896RegorafenibVascular endothelial growth factor receptor 3target
DB08896RegorafenibMast/stem cell growth factor receptor Kittarget
DB08896RegorafenibPlatelet-derived growth factor receptor alphatarget
DB08896RegorafenibPlatelet-derived growth factor receptor betatarget
DB08896RegorafenibFibroblast growth factor receptor 1target
DB08896RegorafenibFibroblast growth factor receptor 2target
DB08896RegorafenibAngiopoietin-1 receptortarget
DB08896RegorafenibDiscoidin domain-containing receptor 2target
DB08896RegorafenibHigh affinity nerve growth factor receptortarget
DB08896RegorafenibEphrin type-A receptor 2target
DB08896RegorafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08896RegorafenibSerine/threonine-protein kinase B-raftarget
DB08896RegorafenibCytochrome P450 2C8enzyme
DB08896RegorafenibCytochrome P450 2C9enzyme
DB08896RegorafenibCytochrome P450 2B6enzyme
DB08896RegorafenibMitogen-activated protein kinase 11target
DB08896RegorafenibTyrosine-protein kinase FRKtarget
DB08896RegorafenibTyrosine-protein kinase ABL1target
DB08896RegorafenibP-glycoprotein 1transporter
DB08896RegorafenibATP-binding cassette sub-family G member 2transporter
DB08896RegorafenibUDP-glucuronosyltransferase 1-1enzyme
DrugDrug NamePhaseStatusCount